Imugene Ltd has released a press release.
Investor Presentation Imugene Eureka Therapeutics
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Imugene
- First patient dosed in phase i clinical trial of checkvacc
- Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
- S&P DJI Announces September 2021 Quarterly Rebalance
- Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
- Appendix 4E and Full Year Statutory Accounts
Later from Imugene
- Clinical Trial Supply Agreement with Merck KGaA and Pfizer
- S&P DJI Announces December 2021 Quarterly Rebalance
- Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
- FDA ind approval for the phase 2 clinical trial of her-vaxx
- Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene